Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.
Metrics to compare | WINL | Peers Peers - average of corresponding metrics from companies closely matching WINL: VIMTALABS, INNOVACAP, SYNGENE, AKUMS, LAURUSLABS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipWINLPeersSector |
---|---|---|---|---|
P/E Ratio | 29.8x | 42.5x | −0.7x | |
PEG Ratio | 3.81 | 1.08 | 0.00 | |
Price/Book | 3.8x | 5.5x | 2.6x | |
Price / LTM Sales | 2.4x | 5.7x | 3.4x | |
Upside (Analyst Target) | - | 13.1% | 39.1% | |
Fair Value Upside | Unlock | −9.8% | 5.4% | Unlock |